Login to Your Account

'Axsome' if they care: IPO seeks $57.5M to advance ZA despite roster of rivals

By Randy Osborne
Staff Writer

Wednesday, October 14, 2015

With would-be competition in the wings from Thar Pharmaceuticals Inc. in complex regional pain syndrome, Axsome Therapeutics Inc. filed for an IPO that would raise as much as $57.5 million to fund AXS-02 (disodium zoledronate) in a phase III trial called Create-1.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription